Table 3.

Effect of baseline characteristics and DTI on OS

Univariable modelMultivariable model
HR95% CIP value∗HR95% CIP value∗
Age at diagnosis 1.03 1.02-1.04 <.001    
Male sex 1.10 0.81-1.49 .5    
Race/ethnicity       
Non-Hispanic White Ref Ref     
Non-Hispanic Black 1.20 0.75-1.93 .4    
Hispanic 0.69 0.45-1.06 .091    
Asian and Pacific Islander 0.83 0.41-1.67 .6    
Hispanic ethnicity 0.65 0.48-0.88 .005 0.70 0.52-0.96 .027 
Preferred language       
English Ref Ref     
Spanish 0.74 0.54-1.02 .063    
Other/unknown 1.53 0.80-2.93 .2    
Insurance status       
Private Ref Ref     
Medicare 1.57 0.71-3.45 .3    
Medicaid 0.95 0.48-1.89 .9    
Uninsured 0.56 0.30-1.04 .067    
ADI national quartile       
1 Ref Ref     
2 0.93 0.49-1.77 .8    
3 0.76 0.43-1.34 .3    
4 0.67 0.38-1.17 .2    
Histology       
DLBCL, NOS, germinal center Ref Ref  Ref Ref  
DLBCL, NOS, nongerminal center 1.63 1.13-2.35 .009 1.29 0.89-1.87 .2 
DLBCL, NOS, unclassifiable 0.93 0.54-1.62 .8 0.94 0.54-1.65 .8 
PBL 3.47 2.02-5.94 <.001 3.82 2.09-6.99 <.001 
DLBCL/HGBCL with MYC/BCL2 rearrangements 2.16 1.02-4.55 .044 1.35 0.63-2.87 .4 
Primary mediastinal LBCL 0.39 0.10-1.61 .2 0.35 0.08-1.50 .2 
T-cell/histiocyte-rich LBCL 1.10 0.34-3.54 .9 0.75 0.23-3.48 .6 
PEL 1.15 0.28-4.74 .3 0.80 0.18-3.45 .8 
Mediastinal gray zone lymphoma 2.05 0.50-8.44 .3 2.03 0.49-8.43 .3 
Intravascular LBCL 0.00 NE >.9 0.00 NE >.9 
Primary cutaneous DLBCL 0.00 NE >.9 0.00 NE >.9 
Stage       
Early stage (I-II) Ref Ref     
Advanced stage (III-IV) 2.91 1.94-4.37 <.001    
ECOG PS       
0-1 Ref Ref     
2-4 3.68 2.58-5.25 <.001    
Unknown 1.52 1.03-2.26 .037    
R-IPI risk group       
Very good Ref Ref  Ref Ref  
Good 2.27 1.08-4.80 .031 1.95 0.91-4.16 .084 
Poor 6.71 3.27-13.8 <.001 4.67 2.23-9.78 <.001 
History of HIV infection 1.45 1.00-2.10 .050 0.70 0.44-1.11 .13 
NCI-CI 1.94 1.51-2.50 <.001 1.53 1.15-2.04 .003 
Hemoglobin, g/dL 0.81 0.76-0.87 <.001 0.89 0.83-0.96 .002 
Serum creatinine, mg/dL 1.29 1.14-1.46 <.001    
Serum albumin, g/dL 0.54 0.44-0.66 <.001    
INR 2.40 1.57-3.65 <.001 2.17 1.24, 3.79 .007 
Serum LDH, ×ULN 1.10 1.07-1.14 <.001    
PNI 0.94 0.92-0.96 <.001    
Time to treatment       
≤6 d Ref Ref     
7-13 d 1.04 0.64-1.70 .9    
14-20 d 1.24 0.75-2.08 .4    
21-27 d 1.20 0.67-2.15 .5    
28-34 d 0.57 0.27-1.24 .2    
≥35 d 0.09 0.62-1.55 .9    
Univariable modelMultivariable model
HR95% CIP value∗HR95% CIP value∗
Age at diagnosis 1.03 1.02-1.04 <.001    
Male sex 1.10 0.81-1.49 .5    
Race/ethnicity       
Non-Hispanic White Ref Ref     
Non-Hispanic Black 1.20 0.75-1.93 .4    
Hispanic 0.69 0.45-1.06 .091    
Asian and Pacific Islander 0.83 0.41-1.67 .6    
Hispanic ethnicity 0.65 0.48-0.88 .005 0.70 0.52-0.96 .027 
Preferred language       
English Ref Ref     
Spanish 0.74 0.54-1.02 .063    
Other/unknown 1.53 0.80-2.93 .2    
Insurance status       
Private Ref Ref     
Medicare 1.57 0.71-3.45 .3    
Medicaid 0.95 0.48-1.89 .9    
Uninsured 0.56 0.30-1.04 .067    
ADI national quartile       
1 Ref Ref     
2 0.93 0.49-1.77 .8    
3 0.76 0.43-1.34 .3    
4 0.67 0.38-1.17 .2    
Histology       
DLBCL, NOS, germinal center Ref Ref  Ref Ref  
DLBCL, NOS, nongerminal center 1.63 1.13-2.35 .009 1.29 0.89-1.87 .2 
DLBCL, NOS, unclassifiable 0.93 0.54-1.62 .8 0.94 0.54-1.65 .8 
PBL 3.47 2.02-5.94 <.001 3.82 2.09-6.99 <.001 
DLBCL/HGBCL with MYC/BCL2 rearrangements 2.16 1.02-4.55 .044 1.35 0.63-2.87 .4 
Primary mediastinal LBCL 0.39 0.10-1.61 .2 0.35 0.08-1.50 .2 
T-cell/histiocyte-rich LBCL 1.10 0.34-3.54 .9 0.75 0.23-3.48 .6 
PEL 1.15 0.28-4.74 .3 0.80 0.18-3.45 .8 
Mediastinal gray zone lymphoma 2.05 0.50-8.44 .3 2.03 0.49-8.43 .3 
Intravascular LBCL 0.00 NE >.9 0.00 NE >.9 
Primary cutaneous DLBCL 0.00 NE >.9 0.00 NE >.9 
Stage       
Early stage (I-II) Ref Ref     
Advanced stage (III-IV) 2.91 1.94-4.37 <.001    
ECOG PS       
0-1 Ref Ref     
2-4 3.68 2.58-5.25 <.001    
Unknown 1.52 1.03-2.26 .037    
R-IPI risk group       
Very good Ref Ref  Ref Ref  
Good 2.27 1.08-4.80 .031 1.95 0.91-4.16 .084 
Poor 6.71 3.27-13.8 <.001 4.67 2.23-9.78 <.001 
History of HIV infection 1.45 1.00-2.10 .050 0.70 0.44-1.11 .13 
NCI-CI 1.94 1.51-2.50 <.001 1.53 1.15-2.04 .003 
Hemoglobin, g/dL 0.81 0.76-0.87 <.001 0.89 0.83-0.96 .002 
Serum creatinine, mg/dL 1.29 1.14-1.46 <.001    
Serum albumin, g/dL 0.54 0.44-0.66 <.001    
INR 2.40 1.57-3.65 <.001 2.17 1.24, 3.79 .007 
Serum LDH, ×ULN 1.10 1.07-1.14 <.001    
PNI 0.94 0.92-0.96 <.001    
Time to treatment       
≤6 d Ref Ref     
7-13 d 1.04 0.64-1.70 .9    
14-20 d 1.24 0.75-2.08 .4    
21-27 d 1.20 0.67-2.15 .5    
28-34 d 0.57 0.27-1.24 .2    
≥35 d 0.09 0.62-1.55 .9    

∗ Bold values denote statistical significance at the P <0.05 level.

BCL2, B-cell leukemia/lymphoma 2 gene; MYC, myelocytomatosis gene; NE, not estimable; NOS, not otherwise specified; Ref, reference.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal